Details of Metabolite
Full List of Protein(s) Regulating This Metabolite | ||||||
---|---|---|---|---|---|---|
Divalent anion:Na symporter (DASS) | ||||||
Solute carrier family 13 member 3 (SLC13A3) | Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s) | |||||
Detailed Information |
Protein Info
![]() |
|||||
Regulating Pair (1) |
Experim Info
![]() |
[1] | ||||
Introduced Variation | Mutation (Ala254Asp) of SLC13A3 | |||||
Induced Change | N-Acetyl-L-aspartic acid concentration: decrease | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Healthy individual | |||||
Details | It is reported that mutation (Ala254Asp) of SLC13A3 leads to the decrease of N-acetyl-L-aspartic acid levels compared with control group. | |||||
Regulating Pair (2) |
Experim Info
![]() |
[1] | ||||
Introduced Variation | Mutation (Gly548Ser) of SLC13A3 | |||||
Induced Change | N-Acetyl-L-aspartic acid concentration: decrease | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Healthy individual | |||||
Details | It is reported that mutation (Gly548Ser) of SLC13A3 leads to the decrease of N-acetyl-L-aspartic acid levels compared with control group. | |||||
Hydrolases (EC 3) | ||||||
GTPase KRas (KRAS) | Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s) | |||||
Detailed Information |
Protein Info
![]() |
|||||
Regulating Pair (1) |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Overexpression of KRAS | |||||
Induced Change | N-Acetyl-L-aspartic acid concentration: decrease (FC = 0.37) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Lung cancer [ICD-11: 2C25] | |||||
Details | It is reported that overexpression of KRAS leads to the decrease of N-acetyl-L-aspartic acid levels compared with control group. | |||||
Regulating Pair (2) |
Experim Info
![]() |
[2] | ||||
Introduced Variation | Overexpression of KRAS | |||||
Induced Change | N-Acetyl-L-aspartic acid concentration: increase (FC = 1.68) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Lung cancer [ICD-11: 2C25] | |||||
Details | It is reported that overexpression of KRAS leads to the increase of N-acetyl-L-aspartic acid levels compared with control group. | |||||
Sulfatase sulf-1 (SULF1) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Protein Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[3] | ||||
Introduced Variation | Knockdown (shRNA) of SULF1 | |||||
Induced Change | N-Acetyl-L-aspartic acid concentration: decrease (FC = 0.32 / 0.37) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Ovarian cancer [ICD-11: 2C73] | |||||
Details | It is reported that knockdown of SULF1 leads to the decrease of N-acetyl-L-aspartic acid levels compared with control group. | |||||
Pore-forming PNC peptide (PNC) | ||||||
Cellular tumor antigen p53 (TP53) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
Detailed Information |
Protein Info
![]() |
|||||
Regulating Pair |
Experim Info
![]() |
[4] | ||||
Introduced Variation | Knockout of TP53 | |||||
Induced Change | N-Acetyl-L-aspartic acid concentration: decrease (Log2 FC=0.72) | |||||
Summary | Introduced Variation
![]() ![]() ![]() |
|||||
Disease Status | Colon cancer [ICD-11: 2B90] | |||||
Details | It is reported that knockout of TP53 leads to the decrease of N-acetyl-L-aspartic acid levels compared with control group. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.